The cell and gene therapy sector is poised to deliver a wave of new therapies with the potential to cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023. While manufacturing and regulatory challenges remain,…

Cell and gene therapies promise to enable broad changes in the healthcare system over the next decade, prompting a growing number of cell and gene therapy companies to join the space. Consider that a cell therapy technique could eliminate the need for immunosuppressive drugs for some organ transplant patients. Cell and gene therapy companies also…

New macular degeneration treatments could offer superior durability to current anti-vascular endothelial growth factor therapy (anti-VEGF). But new drugs must have a similar safety profile to existing therapies to be competitive, according to a UBS briefing note.  The macular degeneration treatment landscape changed significantly in 2005 when FDA approved Macugen (pegaptanib sodium injection) from Pfizer (NYSE:PFE) to…